SDT-102

SDT-102 is a potent and highly selective small molecule inhibitor of Cyclin-dependent kinase 9 (CDK9), developed by Suzhou Jinsheng Pharmaceutical. CDK9 is a critical catalytic subunit of the positive transcription elongation factor b (P-TEFb) complex, which regulates the transcription of key oncogenic drivers and anti-apoptotic proteins, such as MYC and MCL-1, by phosphorylating the C-terminal domain of RNA polymerase II. By inhibiting CDK9, SDT-102 disrupts the transcriptional machinery of cancer cells, leading to a rapid reduction in the levels of short-lived survival proteins and the subsequent induction of apoptosis. The drug is primarily being investigated for the treatment of various hematological malignancies, including relapsed or refractory acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and B-cell malignancies, where it aims to overcome resistance to standard therapies.